Reactions 1468, p35 - 7 Sep 2013

Ropinirole

Dyskinesias: case reportA 46-year-old woman developed dyskinesias following

treatment with ropinirole for Parkinson’s disease.The woman was administered levodopa after diagnosis with

Parkinson’s disease; within 1 month, left foot dyskinesiaensued suggesting that the patient was prone to developingearly dyskinesias with dopaminergic treatment. Levodopa wasslowly withdrawn, and ropinirole was initiated; her ropiniroledose was gradually increased to 9 mg/day then over 6 monthsto 15 mg/day [route not stated]. Severe choreiform dyskinesiasaffecting the pelvis, trunk, hands, feet and fingers developedwithin a month of reaching the highest dose; she scored 8 outof 14 on the Unified Parkinson’s disease Rating Scale-IV.

The woman’s ropinirole dose was reduced to 12 mg/daywith dyskinesia regression; subsequent dose reduction to6 mg/day resulted in resolution of dyskinesias. Ropinirole up to9 mg/day was re-administered for parkinsonism symptoms;however, recurrent mild dyskinesias ensued.

Author comment: "This case highlights that similar toanimal models, some PD patients may develop markeddyskinesias with DA [dopamine agonist] monotherapy whenprimed earlier with levodopa, even with a small dose for ashort duration."Batla A, et al. Ropinirole monotherapy induced severe reversible dyskinesias inParkinson's disease. Movement Disorders 28: 1159-1160, No. 8, Jul 2013.Available from: URL: http://dx.doi.org/10.1002/mds.25318 - UnitedKingdom 803092533

1

Reactions 7 Sep 2013 No. 14680114-9954/13/1468-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved